B.Riley Downgrades Madrigal Pharmaceuticals (MDGL) to Sell
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $488.15 +7.79%
Rating Summary:
20 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
20 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
B.Riley analyst Mayank Mamtani downgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Neutral to Sell with a price target of $155.00.
For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.
Shares of Madrigal Pharmaceuticals closed at $236.54 yesterday.
You May Also Be Interested In
- Madrigal Pharmaceuticals (MDGL) Reiterated at Market Outperform by Citizens
- JPMorgan Downgrades Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) to Neutral
- Goldman Sachs Downgrades Oddity Tech Ltd (ODD) to Sell, Chops PT in Half
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
